{
    "root": "bc5ef851-e144-4d8e-8959-17d142945f4a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KENGREAL",
    "value": "20250521",
    "ingredients": [
        {
            "name": "CANGRELOR",
            "code": "6AQ1Y404U7"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical \n                     Studies (\n                     \n                        14.1\n                     \n                     )].",
    "contraindications": "KENGREAL is intended for administration via a dedicated IV line, only after reconstitution and dilution. ( 2.3 ) Administer 30 mcg/kg intravenous (IV) bolus prior to PCI followed immediately by a 4 mcg/kg/min IV infusion for at least 2 hours or duration of procedure, whichever is longer. ( 2.1 ) To maintain platelet inhibition after discontinuation of KENGREAL infusion, administer an oral P2Y 12 platelet inhibitor. ( 2.2 )",
    "warningsAndPrecautions": "KENGREAL is supplied as a sterile lyophilized powder in single-use 10 mL vials.\n                  \n                     NDC # 10122-620-01: 10 mL vial containing 50 mg cangrelor\n                     NDC # 10122-620-10: 10 count of 10 mL vials containing 50 mg cangrelor\n                  \n                  Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted]. \n                  KENGREAL® is a registered trademeark of Chiesi Farmaceutici S.p.A.\n                  Distributed by:\nChiesi USA, Inc. \nCary, NC  27518\n                  US-126-2-SPL",
    "adverseReactions": "Significant active bleeding ( 4.1 ) Hypersensitivity to KENGREAL or any component of the product ( 4.2 )"
}